Border

Roche nabs FDA clearance

Border

Roche has received FDA clearance for its Alzheimer’s blook biomarker blood test. Trontinemab, currently in phase 3 trials, was developed in collaboration with Eli Lilly and is designed to help assess early signs or Alzheimer’s as well as other causes on cognitive decline in patients over 55 years old.

Click here to read the entire article.

Did you find this helpful? Share with your network!

More Tips From The Bandish Group

Border Line

The Skills Employees Need to Succeed in the Age of AI

◆

Artificial intelligence is changing the workplace, but the skills employees need in the age of AI are not necessarily new.…

#455: Interview Questions for Hiring Managers: How to Identify the Right Candidate

◆

An effective interview is about more than confirming what’s already listed on a candidate’s resume. It’s an opportunity for hiring…

Scroll to Top